Federal prosecutors have launched a new criminal case targeting alleged gray market GLP-1 distribution, signaling what may be the beginning of a broader enforcement shift. At the same time, the new Zepbound KwikPen has quietly arrived in the United States, now appearing in patients' hands without changes to prescription or price.

Meanwhile, early data shows the newly approved Wegovy pill gaining traction among physicians just weeks after launch, potentially expanding access for patients who have been hesitant about injections.

Beyond access and innovation, the episode also explores emerging research on how GLP-1 medications may influence more than weight alone, including their role in inflammatory conditions like psoriasis and their potential connection to nutritional gaps over time.

Christopher walks viewers through what these developments mean in real-world terms for patients who are using GLP-1s to treat the disease of obesity and for those considering treatment.

Downsized News continues to focus on helping the GLP-1 community stay informed as this rapidly evolving space moves forward.